Material Handling Featured Articles
-
FDA Issues New Guidance On Discontinuance Or Interruption In Manufacturing Of Finished Products Or APIs
5/4/2023
In April 2023, the FDA issued an updated guidance superseding and replacing the previous 2020 document about managing drug shortages and explaining what was expected of industry and how the agency was going to manage the shortfalls. This article summarizes the guidance in a helpful FAQ format.
-
India’s CROs & CDMOs Come Of Age In The Global Marketplace
5/4/2023
Most of the top 10 pharmaceutical companies and many large biotech companies today get a portion of their preclinical/clinical research, drug development, and/or manufacturing done in India. While a low price is the initial attraction, there are additional factors that can be more meaningful.
-
5 Emerging Trends In Complex Small Molecule Drug Production
5/3/2023
The small molecule landscape is changing in terms of drug product complexity, molecule potency, manufacturing trends, and industry makeup. How the industry responds will shape the next chapter of small molecule drug development.
-
Recent FDA Inspections In India Indicate New Focus On Tablet Press Operations
4/21/2023
Over the past few years, the FDA investigators in India have shifted their focus away from laboratory and data manipulation and toward a closer look at tablet press operations. The new interest centers on critical process parameters, the automatic weight control system, and more.
-
Risk-Based Strategies For Revalidating Bio/Pharma Equipment & Systems
4/20/2023
While equipment and systems validation is a regulatory requirement, it would take thousands of annual tests to retest all equipment and systems. BioPhorum shares risk-based approaches to new product introduction, controlled temperature chambers, sterilization processes, and more.
-
Strength Biowaivers For Immediate Release Oral Solid Drug Products: European & American Perspectives
4/13/2023
A strength biowaiver is usually claimed for an additional strength when bioequivalence has been established for one strength and the biopharmaceutics classification system biowaiver is not applicable. Six factors need to be considered with additional strength biowaivers, and this article shares the regulatory requirements in the U.S. and Europe.
-
Increase In FDA Inspections + Whistleblower Complaints = Heightened Compliance Scrutiny
3/27/2023
We are seeing a significant increase in manufacturing facility inspections by the FDA and other health authorities globally. We are also seeing an uptick in whistleblower complaints. Why? And how can you navigate it? This article examines the issue.
-
Nanoparticle Engineering Addresses The Challenge Of Poor Aqueous Solubility
3/24/2023
As pharma companies aim to overcome development obstacles, it is important to incorporate GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms.
-
Dispelling 4 Common Myths Of Data Quality Governance
3/9/2023
Achieving robust data quality governance doesn't need to be an unwieldy prospect. Here, we dispel the four common myths of data quality governance and share the three phases of a good data quality governance program.
-
Stability Chambers: Testing, Equipment, And Uses
3/7/2023
Performing stability studies is a critical step in the drug development process. Discover the ways to ensure that your drug is safe and effective as it goes to market.